SINEQUAN (doxepin hydrochloride) by Pfizer is clinical pharmacology the mechanism of action of doxepin is not definitely known. First approved in 1974.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
SINEQUAN (doxepin HCl) is a tricyclic antidepressant approved in 1974 that works by preventing reuptake of norepinephrine at nerve terminals, enhancing adrenergic activity in the central nervous system. It is indicated for depression and anxiety disorders and is available as an oral concentrate formulation. Doxepin has a favorable abuse profile with minimal euphoria and no demonstrated physical tolerance or psychological dependence.
Product is in late lifecycle stage with moderate competitive pressure (30/100), indicating reduced team expansion and shift toward lifecycle management and generic defense strategies.
CLINICAL PHARMACOLOGY The mechanism of action of doxepin is not definitely known. It is not a central nervous system stimulant nor a monoamine oxidase inhibitor. The current hypothesis is that the clinical effects are due, at least in part, to influences on the adrenergic activity at the synapses…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
Worked on SINEQUAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Career opportunities on SINEQUAN are limited and focused on lifecycle management, generic defense, and market access strategy rather than growth or launch activities. Professionals joining this team should expect stable but constrained portfolio responsibilities within Pfizer's legacy CNS business.